This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO-Asia, Singapore 22-24 November 2019

A Phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: a biomarker analysis​

Rafael Rosell, Artem Poltoratskiy, Maximilian Hochmair, Konstantin K. Laktionov, Rodryg Ramlau, Jana Skrickova, Simona Rizzato, Paolo Bidoli, Dariusz Kowalski, Laura Clementi, Agnieszka Cseh, Filippo de Marinis


Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

The value of real-world evidence to clinical practice

Real-world evidence complements clinical trials by providing information on the effectiveness and side-effect profile of therapies in patients treated in routine clinical practice.

The value of real-world evidence to clinical practice

Rate this